ISIvan K. Skiba

Ivan K. Skiba

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ivan K. Skiba has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prediction of the post-hospital complications in patients with decompensated chronic heart failure

    by V. N. Larina, I. K. Skiba, A. V. Skiba, S. E. Arakelov, В. Н. Ларина, И. К. Скиба, А. В. Скиба, С. Э. Аракелов

    Aim . To evaluate the value of the left ventricular global function index (LVGFI) for predicting readmissions and death within 1 year after inpatient treatment for acute decompensated heart failure (ADHF). Material and methods . The study included 100 patients (51% men) aged 73.8±7.5 years hospitalised for ADHF. Follow-up lasted 12 months; the primary composite endpoint was readmission for ADHF and/or posthospital death. All patients underwent a medical history and physical examination, laboratory tests, a six-minute walk test after stabilization, and transthoracic echocardiography with subsequent calculation of the LVGFI. Results . During the follow-up period, 40 patients achieved the primary endpoint (35 patients had readmissions for ADHF alone, and 5 patients had readmissions and death due to ADHF). Based on the outcome, patients were divided into 2 groups: those with readmissions and/or death and those without adverse events. Significant differences were found between the groups in LVGFI (pConclusion . An LVGFI value of <12.6% can be considered a significant predictor of adverse outcomes (rehospitalisation and/or death) during the first year of post hospitalisation in patients who have experienced an episode of ADHF. Using LVGFI may facilitate more accurate posthospital risk stratification and identify the most vulnerable group of patients requiring more intensive monitoring and optimisation of therapy after discharge.

  • Open Access

    Left ventricular global function index as a predictor of unfavorable course of chronic heart failure in the post-hospitalization period

    by V. N. Larina, Ларина В. Н., I. K. Skiba, Скиба И. К.

    Aim. To identify clinical and instrumental predictors of post-hospitalization complications in patients with decompensation of chronic heart failure (CHF). Material and methods. The study included 56 patients hospitalized due to decompensation of CHF (40 (71.4 %) men) aged between 61 and 88 years. Mean observation time was 9 ± 2.9 months. Depending on outcomes at primary endpoint (repeat hospitalization and / or death due to cardiovascular disease), 2 patient groups were formed: 30 patients with an event at the primary endpoint and 26 without it. All patients included in the study underwent bioimpedance analysis (InBody 770), echocardiography (Toshiba Applio 500), 6-minute walk test, quality of life assessment using the Minnesota Living with Heart Failure Questionnaire, and frailty screening using the “Age is not a liability” questionnaire. Bioimpedance analysis allowed to assess total body water, extracellular water, their ratio, body mass index, and percentage of fat tissue. The left ventricular global function index (LVGFI) was calculated using volumetric heart parameters measured during echocardiography. Results. Mean LVGFI value in the group without complications was 15.8 ± 5.4 %; in the group with complications, 12 ± 3.8 %. Threshold LVGFI value for prediction of repeat hospitalization due to CHF within 1 year was 13.05 % with sensitivity of 67 % and specificity of 66 % (area under the ROC curve 0.706; 95 % confidence interval 0.567–0.845; p = 0.004). Bioimpedance signs of water retention at discharge did not show significant correlation with repeat hospitalizations due to CHF (p = 0.475). In patients with CHF and preserved left ventricular ejection function, LVGFI in the group with complications was lower than in the group without complications (p = 0.044). Obesity was not significantly associated with unfavorable outcomes in both the group with complications and the group without them (p = 0.732 and 0.412, respectively). Conclusion. LVGFI value 13.05 % is associated with repeat hospitalizations due to CHF in the 1st year after a decompensation episode (sensitivity 67 %, specificity 66 %). Bioimpedance signs of water retention do not significantly correlate with repeat hospitalization due to CHF.

  • Open Access

    Key updates in clinical guidelines for the management of patients with chronic heart failure

    by Vera N. Larina, Ivan K. Skiba, Ekaterina S. Shcherbina, Andrei A. Lukin

    Chronic heart failure (CHF) is an increasingly important issue in the context of global population aging and advances in health care. This article analyzes key updates in the clinical guidelines of the European Society of Cardiology and the Russian Society of Cardiology for the management of patients with CHF, including revised classification and therapeutic approaches. A systematic search was conducted in PubMed, Google Scholar, and eLibrary.ru. The new classification emphasizes prevention of CHF rather than solely focusing on therapeutic strategies for established disease. The article discusses the roles of sodium–glucose cotransporter 2 inhibitors, angiotensin receptor–neprilysin inhibitors, and highlights the novel mineralocorticoid receptor antagonist finerenone. A synthesis of recent studies and expert opinions provides clinicians with current evidence-based knowledge on the management of CHF. The most important aspect of the updated recommendations is the preventive approach aimed at reducing CHF incidence. These data may be useful for primary care physicians, hospital-based clinicians, and clinical researchers, contributing to improved quality and outcomes of patient care.

  • Open Access

    Biventricular hypertrophic cardiomyopathy with ACTC1 and LDB3 mutations, results of primary prevention of sudden cardiac death: а case report

    by V. N. Larina, Yu. Yu. Varlamova, A. S. Skiba, I. K. Skiba, Ю. Ю. Варламова

    Introduction. Hypertrophic cardiomyopathy (HCM) significantly increases the risk of sudden cardiac death (SCD), especially in young patients. Familial HCM requires an individual approach to risk stratification and determining indications for primary prevention of SCD.Brief description. This case describes a patient with a rare genetic anomaly (a combination of ACTC1 and LDB3 mutations). Thanks to timely diagnosis, indications for a cardioverter-defibrillator implantation were determined, which made it possible to stop an episode of ventricular fibrillation (VF). The case describes the changes of the patient's echocardiographic parameters, morphological features (biventricular myocardial hypertrophy, myocardial bridge), as well as the disease course, therapeutic approaches and 6-year treatment outcomes.Discussion. Careful stratification of SCD risk, including assessment of family history, constant monitoring with dynamic echocardiography and Holter monitoring, allowed timely implantation of a cardioverter-defibrillator and stopping VF. Preventive measures, continuity between the inpatient and outpatient stages saved the patient's life, improved the prognosis and slowed the progression of left ventricular hypertrophy. A rare genetic variant of HCM with mutations in the ACTC1 and LDB3 genes has been described in only three cases over 5 years, which emphasizes the scientific significance of this case. The combination of biventricular hypertrophy, myocardial bridge, and episodes of ventricular tachycardia and VF may be associated with this genotype, which requires further study to improve SCD risk management strategies.

  • Open Access

    Prospects for predicting and preventing the heart failure deterioration: an analytical review

    by V. N. Larina, I. K. Skiba

    Heart failure (CHF) is a syndrome characterized by a progressive course with varying duration of stability period, frequent episodes of clinical deterioration, despite the therapy. HF deterioration often leads to repitalizations and poor prognosis. A possible reduction in rehospitalization rate and prognosis improvement by early administration of optimal therapy and modernization of non-drug approaches is an urgent area of research. An integrated approach using scales, algorithms and relevant therapy strategies can significantly improve treatment outcomes and quality of life in patients with HF.


  • Open Access

    Decompensated heart failure: a reconceptualization in the light of updated consensus statement of the European Society of Cardiology

    by V. N. Larina, V. A. Kokorin, V. G. Larin, V. I. Lunev, N. A. Suvorova, I. K. Skiba, E. S. Shcherbina

    The article presents a brief analytical review of the European Society of Cardiology consensus statement on the definition and clinical features of heart failure (HF) with a summary of the latest results on the treatment and prevention of exacerbation. The main viewpoints are compared with existing approaches in the Russian Federation. The definition and classification of worsening HF (WHF), as well as its main clinical manifestations, epidemiology, outcomes, pathophysiology, approaches to early detection, patterns of in- and outpatient treatment of WHF are discussed. Attention is paid to the terminology necessary to identify a cohort of patients with HF exacerbation with a previously established diagnosis of HF in order to unify approaches to diagnosis and treatment.


  • Open Access

    Twenty-four-year-old patient with heart failure after myocarditis. Results of quadruple therapy: a case report

    by V. N. Larina, I. K. Skiba, T. A. Romanova, A. S. Skiba

    Introduction. The data of epidemiological studies indicate maintaining high prevalence of heart failure (HF) and an unfavorable prognosis for such patients, which creates the need to change the treatment approach. A feature of the case presented is the young age of the patient and a significant effect that was achieved with quadruple therapy for HF with reduced ejection fraction (EF) after myocarditis.Short description. A three-year follow-up of a patient with HFrEF was carried out. In 2019, at the age of 21, the patient had acute myocarditis, diagnosed according to magnetic resonance imaging. The outcome was postmyocarditis cardiosclerosis, complicated by HFrEF. She had two episodes of HF decompensation, followed by hospitalizations in a cardiology hospital. During the treatment, a quadruple therapy was initiated (angiotensin receptor-neprilysin inhibitor, beta-blocker, mineralocorticoid receptor antagonist, sodium-glucose cotransporter 2 inhibitor), against which a significant improve was noted in the form of decrease in congestion symptoms, natriuretic peptide level from 1956 to 501,4 pg/ml, an increase in LVEF from 33% to 39%. The patient is currently on the waiting list for a donor heart transplant.Conclusion. The case report focuses on the complexity of not only the timely diagnosis of myocarditis, but also the treatment of its consequences. The appointment of quadruple therapy for a patient with HF after myocarditis has improved the patient’s clinical condition before heart transplantation. However, this approach needs to be confirmed in a larger number of patients.

  • Open Access

    Heart failure and atrial fibrillation: updates and perspectives

    by V. N. Larina, I. K. Skiba, A. S. Skiba, V. G. Larin, E. A. Vartanyan

    The article discusses modern approaches and features of management, as well as predicting the risk of complications in patients with cardiac arrhythmias, in particular, atrial fibrillation, and the potential of using conservative and interventional treatment methods for heart failure (HF), taking into account updates and achievements in clinical practice. Epidemiological data, algorithms for managing patients with HF and atrial fibrillation, prevention of thromboembolic events, results of studies comparing the effectiveness of different strategies for atrial fibrillation treatment, catheter ablation compared with drug therapy in patients with HF are presented.


  • Open Access

    Summary of updates to the 2021 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure

    by V. N. Larina, I. K. Skiba, A. S. Skiba

    The article provides a summary of the 2021 European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure (CHF). The most significant changes for general practitioners, internists and primary care cardiologists, from our point of view, regards etiology, terminology, as well as algorithms for diagnosing and treating CHF in accordance with phenotypes, new indications to a number of drugs, in particular sodium-glucose cotransporter type 2 inhibitors (dapagliflozin and empagliflozin) with assignment of class I recommended therapy and vericiguat. The article discusses the diagnostic criteria for different heart failure phenotypes, the potential of treating patients with heart failure mildly reduced and preserved ejection fraction.